Literature DB >> 16775595

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.

K J Schjoedt1, K Rossing, T R Juhl, F Boomsma, L Tarnow, P Rossing, H-H Parving.   

Abstract

Reduction of nephrotic range albuminuria is associated with markedly improved renal and cardiovascular outcome in patients with diabetic nephropathy. Aldosterone has been suggested to play a role in the progression of diabetic nephropathy. We therefore aimed to evaluate the short-term effect of aldosterone antagonism with spironolactone on nephrotic range albuminuria and blood pressure in diabetic nephropathy. Twenty Caucasian patients with diabetic nephropathy and nephrotic range albuminuria (>2500 mg/24 h) despite recommended antihypertensive treatment completed this double-masked, randomized crossover trial. Patients were treated in random order with spironolactone 25 mg once daily and matched placebo for 2 months, on top of ongoing antihypertensive treatment, including an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker in maximally recommended doses. Median (range) number of antihypertensive drugs was 3 (2-5). After each treatment period, albuminuria, 24-h ambulatory blood pressure, and glomerular filtration rate (GFR) were determined. Spironolactone on top of recommended renoprotective treatment induced a 32% (95% confidence interval (CI): 21-42%) reduction in albuminuria from (geometric mean (95% CI)) 3718 (2910-4749) mg/24 h on placebo treatment (P<0.001). There was a significant reduction in 24-h blood pressure of 6 (2-10)/4 (2-6) mm Hg and day blood pressure of 7 (3-12)/5 (3-7) mm Hg (P<0.01), whereas night blood pressure remained unchanged. Spironolactone induced an insignificant reversible reduction in GFR of 3 ml/min/1.73 m2 from 64 (27) ml/min/1.73 m2. No patients were excluded due to adverse events. Our results suggest that spironolactone treatment on top of recommended renoprotective treatment including maximal renin-angiotensin system blockade may offer additional renoprotection in patients with diabetic nephropathy and nephrotic range albuminuria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775595     DOI: 10.1038/sj.ki.5001580

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  51 in total

Review 1.  Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.

Authors:  Emaad M Abdel-Rahman; Lawand Saadulla; W Brian Reeves; Alaa S Awad
Journal:  J Gen Intern Med       Date:  2011-10-18       Impact factor: 5.128

2.  Effective antihypertensive strategies for high-risk patients with diabetic nephropathy.

Authors:  Peter Noel Van Buren; Beverley Adams-Huet; Robert Daniel Toto
Journal:  J Investig Med       Date:  2010-12       Impact factor: 2.895

Review 3.  Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.

Authors:  M Dalla Vestra; N Simioni; A Masiero
Journal:  Int Urol Nephrol       Date:  2008-10-29       Impact factor: 2.370

4.  Renal tubular ACE-mediated tubular injury is the major contributor to microalbuminuria in early diabetic nephropathy.

Authors:  Masahiro Eriguchi; Mercury Lin; Michifumi Yamashita; Tuantuan V Zhao; Zakir Khan; Ellen A Bernstein; Susan B Gurley; Romer A Gonzalez-Villalobos; Kenneth E Bernstein; Jorge F Giani
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-29

5.  Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

Authors:  Peter N Van Buren; Beverley Adams-Huet; Mark Nguyen; Christopher Molina; Robert D Toto
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

Review 6.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

Review 7.  Clinical therapeutic strategies for early stage of diabetic kidney disease.

Authors:  Munehiro Kitada; Keizo Kanasaki; Daisuke Koya
Journal:  World J Diabetes       Date:  2014-06-15

Review 8.  Therapeutic approaches to diabetic nephropathy--beyond the RAS.

Authors:  Beatriz Fernandez-Fernandez; Alberto Ortiz; Carmen Gomez-Guerrero; Jesus Egido
Journal:  Nat Rev Nephrol       Date:  2014-05-06       Impact factor: 28.314

Review 9.  The ubiquitous mineralocorticoid receptor: clinical implications.

Authors:  Urseline A Hawkins; Elise P Gomez-Sanchez; Clara M Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

10.  Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods.

Authors:  Katarina Roos; Anders Hogner; Derek Ogg; Martin J Packer; Eva Hansson; Kenneth L Granberg; Emma Evertsson; Anneli Nordqvist
Journal:  J Comput Aided Mol Des       Date:  2015-11-16       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.